XML 28 R11.htm IDEA: XBRL DOCUMENT v3.24.0.1
Investments and Fair Value Measurements
12 Months Ended
Dec. 31, 2023
Fair Value Disclosures [Abstract]  
Investments and Fair Value Measurements
3. INVESTMENTS AND FAIR VALUE MEASUREMENTS
Strategic Investments

Marketable Equity Securities

Our short-term investments consist of marketable equity securities. As of December 31, 2023 and January 1, 2023, the fair value of our marketable equity securities totaled $6 million and $26 million, respectively.

Gains and losses recognized in other (expense) income, net on our marketable equity securities were as follows:
In millions202320222021
Net (losses) recognized during the period on marketable equity securities$(2)$(81)$(52)
Less: Net (losses) recognized during the period on marketable equity securities sold during the period(2)— (89)
Net unrealized (losses) gains recognized during the period on marketable equity securities still held at the reporting date$ $(81)$37 

Non-Marketable Equity Securities

As of both December 31, 2023 and January 1, 2023, the aggregate carrying amounts of our non-marketable equity securities without readily determinable fair values, included in other assets, were $28 million.

Revenue recognized from transactions with our strategic investees was $69 million, $113 million, and $74 million in 2023, 2022, and 2021, respectively.

Venture Funds

We invest in two venture capital investment funds (the Funds) with capital commitments of $100 million, callable through April 2026, and up to $150 million, callable through July 2029, respectively, of which $4 million and up to $71 million, respectively, remained callable as of December 31, 2023. Our investments in the Funds are accounted for as equity-method investments. The aggregate carrying amounts of the Funds, included in other assets, were $168 million and $183 million as of December 31, 2023 and January 1, 2023, respectively. We recorded net unrealized losses of $33 million and $25 million in 2023 and 2022, respectively, and a net unrealized gain of $55 million in 2021, in other (expense) income, net.
Fair Value Measurements

The following table presents the hierarchy for assets and liabilities measured at fair value on a recurring basis:

December 31, 2023January 1, 2023
In millionsLevel 1Level 2Level 3TotalLevel 1Level 2Level 3Total
Assets:
Money market funds (cash equivalents)$774 $ $ $774 $1,642 $— $— $1,642 
Marketable equity securities6   6 26 — — 26 
Helix contingent value right  68 68 — — 58 58 
Deferred compensation plan assets 61  61 — 52 — 52 
Total assets measured at fair value$780 $61 $68 $909 $1,668 $52 $58 $1,778 
Liabilities:
Contingent consideration liabilities$ $ $387 $387 $— $— $412 $412 
Deferred compensation plan liability 59  59 — 51 — 51 
Total liabilities measured at fair value$ $59 $387 $446 $— $51 $412 $463 

Our marketable equity securities are measured at fair value based on quoted trade prices in active markets.

Our deferred compensation plan assets consist primarily of investments in life insurance contracts carried at cash surrender value, which reflects the net asset value of the underlying publicly traded mutual funds. We perform control procedures to corroborate the fair value of our holdings, including comparing valuations obtained from our investment service provider to valuations reported by our asset custodians, validating pricing sources and models, and reviewing key model inputs, if necessary.

Helix Contingent Value Right

In conjunction with the deconsolidation of Helix Holdings I, LLC (Helix) in April 2019, we received a contingent value right with a 7-year term that entitles us to consideration dependent upon the outcome of Helix’s future financing and/or liquidity events. We elected the fair value option to measure the contingent value right received from Helix. The fair value of the contingent value right, included in other assets, is derived using a Monte Carlo simulation. Estimates and assumptions used in the Monte Carlo simulation include probabilities related to the timing and outcome of future financing and/or liquidity events, assumptions regarding collectability and volatility, and an estimated equity value of Helix. These unobservable inputs represent a Level 3 measurement because they are supported by little or no market activity and reflect our own assumptions in measuring fair value.

Changes in the fair value of the Helix contingent value right, included in other (expense) income, net were as follows:

In millions
Balance as of January 3, 2021$35 
Change in estimated fair value30 
Balance as of January 2, 202265 
Change in estimated fair value(7)
Balance as of January 1, 202358 
Change in estimated fair value10 
Balance as of December 31, 2023$68 
Contingent Consideration Liabilities
We reassess the fair value of contingent consideration related to acquisitions on a quarterly basis. Changes in the fair value of contingent consideration subsequent to the acquisition date are recognized in selling, general and administrative expense. The contingent value rights issued as part of the GRAIL acquisition entitle the holders to receive future cash payments on a quarterly basis (Covered Revenue Payments) representing a pro rata portion of certain GRAIL-related revenues (Covered Revenues) each year for a 12-year period. As defined in the Contingent Value Rights Agreement, this will reflect a 2.5% payment right to the first $1 billion of revenue each year for 12 years. Revenue above $1 billion each year will be subject to a 9% contingent payment right during this same period. Covered Revenues for the period Q4 2022 through Q3 2023 were $85 million in aggregate and Covered Revenues for the period Q4 2021 through Q3 2022 were $42 million in aggregate, driven primarily by sales of GRAIL’s Galleri test. Covered Revenue Payments relating to such periods were approximately $803,000 and $396,000 in 2023 and 2022, respectively. Pursuant to the Contingent Value Rights Agreement, a portion of the Covered Revenue Payments in 2022 were applied to reimburse us for certain expenses. We use a Monte Carlo simulation to estimate the fair value of contingent consideration related to the GRAIL acquisition. Estimates and assumptions used in the Monte Carlo simulation include forecasted revenues for GRAIL, a revenue risk premium, a revenue volatility estimate, an operational leverage ratio and a counterparty credit spread. These unobservable inputs represent a Level 3 measurement because they are supported by little or no market activity and reflect our own assumptions in measuring fair value. The fair value of our contingent consideration liability related to GRAIL was $387 million and $412 million as of December 31, 2023 and January 1, 2023, respectively, of which $385 million and $411 million, respectively, was included in other long-term liabilities, with the remaining balances included in accrued liabilities.

Changes in the estimated fair value of our contingent consideration liabilities were as follows:

In millions
Balance as of January 3, 2021$— 
Acquisition of GRAIL762 
Other acquisition14 
Measurement period adjustment related to GRAIL acquisition(5)
Cash payments(15)
Exchange of GRAIL contingent value rights(145)
Change in estimated fair value
Balance as of January 2, 2022615 
Acquisition
Change in estimated fair value(205)
Balance as of January 1, 2023412 
Change in estimated fair value(24)
Cash payments(1)
Balance as of December 31, 2023$387 

In December 2021, we exchanged approximately 73 million contingent value rights, that were issued as part of the GRAIL acquisition, for an aggregate cash payment of $57 million and the issuance of $2 million in shares of our common stock. As a result of the exchange, we recognized a gain of $86 million in other (expense) income, net in 2021, which represented the difference between the fair value of the contingent consideration liability for the contingent value rights exchanged of $145 million and the total consideration transferred of $59 million.
We recorded a contingent consideration liability of $14 million as a result of an acquisition completed in Q2 2021. The acquisition-date fair value of the contingent consideration was derived using the income approach. Assumptions used to estimate the liability included the probability of achieving certain milestones and a discount rate. These unobservable inputs represented a Level 3 measurement because they were supported by little or no market activity and reflected our own assumptions in measuring fair value. We recorded an expense of $1 million in selling, general and administrative expense in 2021 due to the change in estimated fair value of the contingent consideration and made a payment of $15 million in Q4 2021 upon achievement of the milestones.